Drug Profile

MLN 519

Alternative Names: LDP 519; MLN519; PN 05; PS 519

Latest Information Update: 29 Jun 2006

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Millennium Pharmaceuticals
Class Anti-inflammatories; Lactones
Mechanism of Action Immunomodulators; Proteasome inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Inflammation; Reperfusion injury; Stroke

Most Recent Events

31 May 2004 A preclinical study has been added to the Neurological pharmacodynamics section
17 Dec 2003 Preclinical data from a media release have been added to the Neurological disorders pharmacodynamics section
17 Mar 2003 PAION has terminated its licence for MLN 519 in Europe

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com